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Abstract: Diffuse idiopathic skeletal hyperostosis (DISH) is characterised by ectopic ossification
along the anterior spine and the outer intervertebral discs (IVD). However, the centre of the IVD,
i.e., the nucleus pulposus, always remains unaffected, which could be due to the inhibition of the
bone morphogenetic protein (BMP) pathway. In this study, we investigated the transcriptome for
the BMP pathway of DISH-IVD cells versus disc cells of traumatic or degenerative discs. The disc
cells originated from nucleus pulposus (NP), annulus fibrosus (AF) and from cartilaginous endplate
(CEP) tissue. Here, ninety genes of the transforming growth factor β-BMP signalling pathway were
screened by qPCR. Furthermore, the protein expression of genes of interest was further investigated
by immune-staining and semi-quantitative microscopy. IVDs of three DISH patients were tested
against three control patients (same disc level and similar age). Early Growth Response 2 (EGR2)
and Interleukin 6 (IL6) were both significantly up-regulated in DISH-IVD cells compared to controls
(12.8 ± 7.6-fold and 54.0 ± 46.5-fold, respectively, means ± SEM). Furthermore, Insulin-like Growth
Factor 1 (IGF1) tended to be up-regulated in DISH-IVD donors, i.e., 174.13 ± 120.6-fold. IGF1 was
already known as a serum marker for DISH and other rheumatoid diseases and is confirmed here to
play a possible key role in DISH-IVD.
Keywords: low back pain; diffuse idiopathic skeletal hyperostosis; RNA extraction; qPCR; TGFβ-
pathway; immune-histochemistry; Interleukin 6; Insulin-like growth factor 1; early growth response 2
1. Introduction
Diffuse idiopathic skeletal hyperostosis (DISH), also known as Forestier’s disease,
was first described by Forestier and Rotes-Querol in 1950 [1]. The authors characterised
this disorder by spinal stiffness, osteophytosis, and aberrant new-bone formation along the
spine’s anterior lateral aspect. The underlying causes are yet unknown and thus are called
“idiopathic” [2]. DISH is generally characterised by ossification of ligamentous insertions
(fibro-osteosis) and ossification or calcifications of tendons, ligaments, fasciae, joint capsule
and annulus fibrosus (AF) fibres [3–5]. Furthermore, DISH increases the amount of normal
cancellous and cortical bone. Moreover, a tendency of post-operative heterotopic bone
formation has been observed [6]. The incidence of DISH, however, remains unknown, but
it seems that factors of metabolic, endocrine, genetic, and epigenetics seem to be important
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in the development of this condition [4,7]. This disease mainly affects the elderly and
is more frequent in men (65%) than in women, and the prevalence also increases with
age (48–85) [8,9]. DISH patients often suffer from severe pain and need special treatment.
Hence, the disease is often co-diagnosed with osteoarthritis [10,11].
Recently, Kuperus et al. (2016) [12] investigated the relationship between DISH and
IVD degeneration. These authors found that partial or complete bone bridges were often
present in DISH cadaveric IVDs that were only rarely found in healthy cadaveric controls.
However, the disc height and degeneration level of DISH and control specimens were com-
parable. This specific feature also distinguishes the DISH condition from spondylosis [11].
To date, only very few molecular pathway studies have been conducted on the effect of
DISH on IVDs. ElMiedany et al. (2000) proposed that the new formation of bone is mainly
driven by abnormal cell growth/activity in the bony-ligamentous region [13]. Previous
studies on the metabolomics of this disease found that patients suffering from symptomatic
DISH disease have elevated levels of growth hormone (GH) and insulin-like growth factor
1 (IGF1) compared to patients of the same age and gender [9,14–19]. Thus, the molecular
mechanism of DISH and the specific characteristics of underlying cell signalling remain
obscure. Bone morphogenic proteins (BMPs), such as BMP2, BMP4, BMP6, BMP7, and
BMP9, have shown their potential to induce the osteogenic differentiation of stromal cells
and osteoblastic lineage cells in vitro and in vivo [20–23]. Furthermore, the recent literature
has summarised and questioned the supra-physiological usage of BMP2 for the application
of improved spinal fusion [24]. Thus, recently it has been hypothesised that BMP inhibitors
could be the main reason for the lacking effect of BMP2 for improved spinal fusion [25–28].
In this context, it is of uttermost interest to analyse the transcriptome of DISH-IVDs in
more detail, as all the surrounding tissue starts to ossify but not the IVD itself, which seems
to be resistant to osteogenic signalling [29].
Hence, the current study aimed to compare the gene expression at the BMP path-
way of cells of IVDs from patients suffering from DISH disease and compare it with cells
originating from traumatic or degenerative IVDs. We assumed that trauma discs, espe-
cially from younger patients, contain presumably “healthier” cells that could be defined
as a “control”. Here, we investigated whether DISH disease is linked to alterations in
BMP/TGFβ signalling pathways to gain further insights into how the DISH-IVD was
affected by this idiopathic disease at the molecular level. We hypothesised that IVDs of
patients diagnosed with DISH demonstrate specific gene expression changes affecting the
TGFβ/BMP pathway compared to degenerative IVDs or trauma patients.
2. Materials and Methods
2.1. IVD Donor Materials and Cell Isolation
Human IVDs were obtained from patients suffering from DISH disease. As controls,
traumatic or degenerative IVDs of patients undergoing spinal surgery were used (Table 1).
Patients gave their written consent, and procedures were approved by the ethics committee
of the Canton of Bern. Tissues were processed within 24 h after surgery.
Human IVD tissue was separated into nucleus pulposus (NP), annulus fibrosus
(AF) and cartilaginous endplate (CEP) tissue by an experienced surgeon or processed as
mixed IVD. Cell isolation from the native extracellular matrix was performed as described
earlier [28]. Briefly, tissue was enzymatically digested by 1 h in pronase (Roche, Basel,
Switzerland) followed by overnight incubation in collagenase type 2 (Worthington, London,
United Kingdom). Subsequent expansion of NP cells (NPC), AF cells (AFC), and CEP cells
(CEPC) followed in proliferation medium (low-glucose (1g/L) Dulbecco’s Modified Eagle
Medium (LG-DMEM) supplemented with 10% FBS and 1% P/S).
IVD cells were obtained from six DISH donors aged from 65 to 84 years (72.3 ± 3.1
years) and three “control” donors, which were lacking symptoms of DISH, suffering from
degenerated or traumatic discs aged from 17 to 66 years (45 ± 14.5 years).
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Table 1. Donor list of intervertebral disc cells. Cell type:nucleus pulposus (N), annulus fibrosus (A), cartilaginous endplate
(CEP), C = cervical, L = lumbar, intervertebral disc mixed (IVD) Sex: Female (F), Male (M). Disc condition: Degenerated (D),
Trauma (T), Pfirrmann Grade (PG).
Donor Groups Used in this Study
DISH Control
Patient # Cell Type Age Sex SpinalLevel Patient # Cell Type Age Sex
Spinal
Level Disc Condition
1 N/A/CEP 72 M L4/L5 1 N/A/CE 66 F L4/L5 D; PG3
2 N/A/CEP 65 F L11/T12 2 N/A/CE 52 M L11/T12 T; PG3
3 IVD 66 M L5/L6 3 IVD 17 M C5/C6 T
4 N/A 68 M L11/T12 2 N/A/CE 52 M L11/T12 T; PG3
5 A/CEP 79 M C5/C6 3 IVD 17 M C5/C6 T
6 A 84 M L10/T11 2 N/A/CE 52 M L11/T12 T; PG3
2.2. Analysis of Specific Gene Expression in Human Primary IVD Cells with Quantitative
Polymerase Chain Reaction (qPCR)
Cells were cultured at passage 1–2 (P1–2) in monolayer, and then trypsinised before
2 Mio of cells were lysed directly with TRI. The extraction of total RNA was performed
as described in the methods before [28,30]. Prior qPCR RNA integrity and purity were
checked on selected samples by the Experion™ Automated Electrophoresis System (Bio-
Rad, Reinach, Switzerland). Any possible remaining DNA was digested by using DNase
I (AMP-D1, Sigma-Aldrich, Buchs, Switzerland) for 15 min. Reverse transcription was
performed by using all-in-one cDNA Synthesis SuperMix (Bimake distributed by LuBio-
Science GmbH, Lucerne, Switzerland). Real-time PCR was performed using SYBR Green
PCR master mix on a CFX96touch qPCR system (all from Bio-Rad). Ninety genes (Table 2)
were tested with PrimePCR™ Pathway plate 96 well (PrimePCR™ TGFβ BMP Signalling
Pathway Plus H96, 90 genes, Bio-Rad, US). The qPCR was run using a two-step protocol
with an annealing temperature of 60 ◦C for 30 s and 95 ◦C for 5 s for 40 cycles (according to
the recommendations of the manufacturer). Amplicon specificity was ensured by perform-
ing a melting curve analysis after cycling. CFX manager software version 3.1 (Bio-Rad) was
used for the quantification analysis of normalised relative gene expression. The number
of PCR cycles needed for each sample to reach the threshold level was recorded as the
Cq value [31]. Values were normalised relative to two reference genes (18S and ACTB).
DISH and control cells were compared in scatter plots and RNA transcripts that differed
more than four times were indicated in red (up-regulated in DISH patients) or in green
(down-regulated in DISH patients).
Table 2. List of genes tested in PrimePCR™ TGFβ BMP Signalling Pathway Plus H96, 90 genes, Bio-Rad, US.
Name Description Name Description Name Description





ACTC1 Actin Alpha CardiacMuscle 1 ENG Endoglin NOV
Nephroblastoma
overexpressed
ACVR1 Activin A Receptor Type 1 FAS Fas Cell SurfaceDeath Receptor PDGFB
Platelet-Derived Growth
Factor Subunit B
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Table 2. Cont.
Name Description Name Description Name Description




RPLP0 Ribosomal Protein LateralStalk Subunit P0




SERPINE1 Serpine Family E Member 1



























SMAD4 SMAD Family Member 4




SMAD6 SMAD Family Member 6
BMP2 Bone MorphogeneticProtein 2 GSC
Goosecoid
Homeobox SMAD7 SMAD Family Member 7
BMP3 Bone MorphogeneticProtein 3 GUSB
Glucuronidase
Beta SMURF1
SMAD Specific E3 Ubiquitin
Protein Ligase 1












STAT1 Signal Transducer andActivator of Transcription 1




STK38L Serine/Threonine Kinase23 Like
BMP7 Bone MorphogeneticProtein 7 ID2
Inhibitor of DNA
Binding 2 TBP TATA-Box Binding Protein




TGFB1 Transforming GrowthFactor Beta 1
BMPR1A Bone MorphogeneticProtein Receptor, Type IA IGF1
Insulin-Like








TGFB2 Transforming GrowthFactor Beta 2
BMPR2 Bone MorphogeneticProtein Receptor, Type II IL6 Interleukin 6 TGFB3
Transforming Growth
Factor Beta 3
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Table 2. Cont.
Name Description Name Description Name Description










TGFBR1 Transforming GrowthFactor Beta Receptor 1




TGFBR2 Transforming GrowthFactor Beta Receptor 2
CHRD Chordin KLHL24 Kelch Like FamilyMember 24 TGFBR3
Transforming Growth
Factor Beta Receptor 3




TGIF1 TGFB Induced FactorHomeobox 1













TNFSF10 TNF Superfamily Member10




UBASH3B Ubiquitin Associated andSH3 Domain Containing B
2.3. Statistical Analysis and Visualisation of Heat Maps and Clustering
Relative gene expression was quantified between DISH and “control” patients. Statis-
tical significance was tested using a non-parametric Mann–Whitney U test due to relatively
low sample sizes using Prism 7.0d for Mac OS X (GraphPad, La Jolla, CA, USA). Non-
parametric distribution was assumed. Consequently, statistical significance was determined
using the Mann–Whitney U test. A p-value < 0.05 was considered to be significant. Relative
gene expression data were normalised using CFX manager software 3.1. Heat mapping and
hierarchical clustering was performed in CFX manager based on the degree of similarity
of expression for different samples, and a heat map was generated alongside as imple-
mented in CFX manager software. Pairwise scatter plot analysis was performed between
DISH tissues versus “control” tissues and relative gene expression differences > 4.0 were
highlighted (Supplementary Figure S1).
2.4. Immunocytochemistry
Cells at P1/P2 of frozen DISH donor 1 and control donor 1 (Table 1) were thawed
and seeded at a density of 8000 cells/mL in glass chamber slides with removable 12-
well silicone chambers for immunofluorescence staining (growth area per well 1.9 cm2)
(Vitaris, Baar, Switzerland). Cells were then cultured in LG-DMEM supplemented with
10% FBS and 1% P/S until they reached 70% confluency. Cells were then fixed in 4%
buffered paraformaldehyde (Sigma-Aldrich) for 15 min and stored in 70% ethanol at 4
◦C prior to staining. Fixed cells were permeabilized with 0.2% Triton (Sigma-Aldrich)
for 15 min. Again, the cells were washed three times with Tris-buffered saline (TBS) for
5 min. Subsequently, cells were blocked with 10% FCS in 0.025% Tris-buffered saline
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containing Tween 20 (TBS-T) for 30 min at room temperature. After blocking, cells were
incubated overnight at 4 ◦C using a primary antibody (AB) in blocking solution and under
continuous agitation (see Table 3). Secondary ABs were applied in 1:200 dilution in 0.025%
TBS-T for 3 h at room temperature (Alexa Fluor® 555 Rabbit Anti-Goat IgG (H+L), Alexa
Fluor® 555 Goat anti-mouse SFX-kit, Alexa Fluor® 488 Goat anti-Rabbit SFX Kit, Molecular
Probes, Life Technologies, Basel, Switzerland). Cells were viewed under a microscope
(Leica DMI4000 (Biosystems inc., Muttenz, Switzerland) and LAS AF Software).
Table 3. Primary antibodies used for immunohistochemistry.
Primary AB Source Concentration ICC
Mouse GDF5 Polyclonal Goat IgG (Biotechne, Zug, Switzerland) 5 µg/mL
Human IL6 Monoclonal mouse IgG (Biotechne) 16 µg/mL
Human IGF1 Polyclonal Goat IgG (Biotechne) 5 µg/mL
Human BMP2 Polyclonal Rabbit (Novusbio, Zug, Switzerland) 5.75 µg/mL
Human EGR2 Polyclonal Rabbit (Novusbio) 5 µg/mL
Human GDF6 Rabbit polyclonal–C terminal (Abcam, Cambridge, UK) 1:100
3. Results
3.1. Prime PCR of DISH and Traumatic/Degenerative Discs
PrimePCR™ screening for 90 genes of the BMP pathway was initially run. Most
strikingly, these data revealed a significant mean up-regulation of EGR2 (12.8 ± 7.6-fold,
p = 0.0068, overall mean ± SEM of all comparisons) and of interleukin 6 (IL6) (54.0 ± 46.5-fold,
p = 0.0005) in DISH-IVDs relative to the “control” discs (Figure 1, Supplementary Figure
S1). Furthermore, IGF1 tended to be up-regulated in DISH-IVD donors (174.1 ± 120.6-fold,
p = 0.1704), although this was non-significant. Growth and Differentiation Factor 5 (GDF5)
and GDF6 both tended to be down-regulated in the DISH-IVDs (i.e., −11.5 ± 10.0, p = 0.26
and −3.7 ± 3.1 p = 0.30, respectively, Figure 1, Supplementary Figure S1). However, these
differences were not significant.
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Clustering the gene expression profiles of the 19 analysed samples of the three control
patients and the six DISH patients revealed that not all samples clustered together as
expected (Figure 2). However, it seems also evident that the hierarchical phenogram
generated two main clusters of phenotypes with a similar TGFβ pathway pattern (Figure 2).
Clade 1 consisted of mainly DISH samples, and clade 2 consisted mainly of control samples.
However, samples of DISH patients 3 and 5 (i.e., D P3 IVDC and D P5 AFC and EPC)
showed a phenotype more similar to the cells of the included trauma patients. On the other
hand, the dendrogram confirmed that cells originating from different tissue types of the
IVD from the same patient were grouped closely together, which was expected.
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3.2. Immunocytochemistry of IGF1, IL6, EGR2, BMP2, GDF5, and GDF6
Gene expression differences, which showed a more than four times up- or down-
regulation in PrimePCR™ between DISH and “control” patients (Figure 1), were further
evaluated using immune-staining of isolated cells grown in monolayer. BMP2 showed a
stronger signal in the AFC in DISH than in “control” patients, as found in the relative gene
expression (Figure 3). Furthermore, the EGR staining was more intense in the AFC and
NPC in DISH compared to control patients’ staining, as was also found in PrimePCR™.
In particular, the AFC showed a strong immunocytochemistry staining for EGR2 and
BMP2 compared to the AFC of the control patient. Additionally, IGF1 staining of DISH
was more intense compared to control patients, as the NPC and the AFC showed almost no
IGF1 protein expression by immunocytochemistry staining. GDF5 and GDF6 were overall
more strongly stained in control cells compared to DISH cells.
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(green), respectively.
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4. Discussion
In this study, we report, for the first time, on the phenotypic changes in IVD cells from
DISH patients compared to IVD cells from supposedly “healthier” cells from younger and
mid-aged trauma patients (Table 1). We observed the consistent up-regulation of IGF-1,
and EGR2, which seems to be a hallmark of the DISH-IVD cells [4,29], and cells from
degenerative discs showed a different BMP gene-related transcript and protein expression
(Figures 1–3). One of the main limitations of this study was the relatively small sample
size. Thus, sample collection from a single hospital was a challenge, and future studies
should recruit IVD material from bigger cohorts and multiple populations and etiologies.
Additionally, the “controls” used in the study were not truly healthy IVDs, as they were
either degenerative or traumatic discs. In this respect, a comparison of fresh cadaveric
IVD material of undegenerated nature would be essential for any future investigations.
Acquiring more DISH and matching healthy IVDs are required to support our first findings
regarding the phenotypic status of the IVD during DISH disease. Moreover, it should be
investigated whether DISH affects the overall phenotype of IVD cells and their tissues. To
answer this particular question, complete transcriptome analyses using bulk RNA next-
generation sequencing would definitively shed new light on the better understanding of
DISH pathology and into yet-unidentified modified pathways of this disease.
Since the discovery of DISH, various studies, especially concerning the metabolic
conditions of these patients, were conducted. Nevertheless, this disease is still poorly
understood. In the current study, we investigated the changes at the transcript and the
protein expression level of IVDs from patients diagnosed with DISH. We observed signifi-
cant up-regulation of EGR2 and IL6 and a trend of higher IGF1 expression at the transcript
level. These changes could be confirmed qualitatively at the protein level using immuno-
histochemistry. For GDF5 and GDF6, we noticed, for both genes, a down-regulation in
gene expression in the IVD of those patients, though this was not statistically significant.
However, these differences were not apparent at the protein level (Figure 3). This gene
expression profile points to an involvement in inflammation in DISH, recently identified in
a review by Mader et al. (2021) [29].
Previous research by Levi et al. (1996) [32] has shown that EGR2-/- mice develop
skeletal abnormalities, i.e., reducing length and thickness in newly formed bone and
calcified trabeculae. These phenomena were explained by the activation of EGR2 in
a subpopulation of hypertrophic chondrocytes of the growth plate and differentiating
osteoblasts (OBs) [32]. Furthermore, Leclerc et al. (2008) [33] showed up-regulation of
EGR2 expression during the late stage of OB differentiation in-vitro. Furthermore, Zaman
et al. (2012) [34] found that EGR2 expression was up-regulated in the osteosarcoma-derived
UMR106 cell line through IGF1 stimulation. The cause of the observed up-regulation of
EGR2 and its role in DISH-IVD cells would need to be further explored.
DISH has been associated with the change in inflammatory mediators [35]. Interleukin
1 (IL1) and IL6 are increased in DISH patients through the activation of nuclear factor
kappa-B (NF-κB) ligand, and these cytokines stimulate the proliferation of OBs and bone
deposition [29,35,36]. Two other studies [37,38] have also suggested the stimulating effect
of IL6 on bone formation and turnover. Kang et al. (1996) [39] further demonstrated an
increased concentration of IL6 in herniated lumbar discs, which may indicate an association
with degradation of the IVD. We could most interestingly confirm the involvement of IL6 in
our data, as it was up-regulated in all analysed DISH-IVDs (Figure 1, and Supplementary
Figure S1).
Several studies have shown the possible overlap between DISH, obesity and Diabetes
mellitus, with a pathogenic effect of insulin, IGF1 and GH [40–43]. Yakar et al. (2002) [44]
demonstrated an association of circulating blood serum IGF1 and bone mass in mice with
reduced IGF1 serum levels. These mice showed abnormalities in bone formation including
decreased bone mineral density and cortical thickness [44]. However, IGF1 is not only
present in the serum but also readily available in the skeletal environment. The skeletal
homeostasis is driven by the release of IGF1 during bone modelling and remodelling, as
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an essential mitogen and chemotactic player in the skeleton [45]. It also could have been
shown that IGF1 stimulates IVD cell proliferation and matrix synthesis in-vitro [46].
GDF5, GDF6, and BMP2 are members of the TGFβ superfamily, with GDF5 and
GDF6 being involved in the growth and development of cartilage and bone tissues [47].
Moreover, in the IVD, GDF5 seems to play a role in altering homeostasis, as several studies
showed its beneficial effect of inducing cell proliferation, proteoglycan stimulation and
COL2 expression [48,49]. Furthermore, GDF6 plays a role in spinal column development,
especially in IVD development and homeostasis [50,51]. Both GDF5 and GDF6 have
recently been shown to promote mesenchymal stromal cells towards a discogenic pheno-
type [52–56]. Interestingly, both GDF5 and GDF6 were down-regulated in several cell types
of DISH-IVDs compared to controls. This might indicate a DISH-related change of the
discogenic phenotype in these patients.
With increasing rates of obesity and type 2 Diabetes, the prevalence of DISH is also
expected to rise in the future, possibly also affecting younger patients below 50 years
of age [29,57]. This development is leading to an urgency to further understand and
investigate this disease and its cell signalling.
5. Conclusions
• DISH-IVD, in contrast to IVD obtained from trauma, showed an up-regulation of
EGR2 and IL-6, and IGF-1 tended to be up-regulated.
• Dysregulation of IGF-1 has been proposed for DISH-patients to be a serum-specific
marker, and our data from IVD tissue pointed in this direction [4].
• GDF5 and GDF6 tended to be down-regulated in DISH-IVD compared to trauma-IVD.
• The observed differences in gene expression and protein differences could also be a
result of factors other than DISH such as age and gender bias [58].
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/app11094072/s1: Figure S1: TGFβ pathway transcriptome analysis of three donors with age-
and disc level matched controls.
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BMP Bone morphogenetic protein
BMP2 Bone morphogenetic protein 2




DISH Diffuse idiopathic skeletal hyperostosis
EGR2 Early growth response 2
GDF5 Growth and differentiation factor 5
GDF6 Growth and differentiation factor 6
GH Growth hormone





LG-DMEM Low-glucose Dulbecco’s Modified Eagle Medium
NP Nucleus pulposus
OB Osteoblast
TBS-T Tris-buffered saline containing Tween 20
TGF-β Transforming growth factor β
P Passage
PG Pfirrmann grade
qPCR Quantitative real-time Polymerase Chain Reaction
T Trauma
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